Ceritinib

Description

This page contains brief details about the drug ceritinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Ceritinib is a targeted cancer therapy drug belonging to the class of tyrosine kinase inhibitors. It was approved for its medical use on 29th April 2014.

Mechanism of Action of Ceritinib

Ceritinib Capsule is indicated to treat the advanced stage of lung cancer as an initial treatment and is also recommended when anticancer treatment with Crizotinib did not work. It is prescribed to treat non-small cell lung cancer caused by defects in the ALK-positive genes.

Uses of Ceritinib

Ceritinib Capsule is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a tyrosine kinase inhibitor. Anaplastic lymphoma kinase is a significant gene that result in non-small cell lung cancer by undergoing mutation. Ceritinib inhibits ALK genes and stops the growth and development of cancer cells by shrinking them.

Ceritinib Dosage available

Ceritinib is available in the form of hard gelatin capsules in a dose of 150mg. The recommended dose is three 150mg capsules once daily. It is advisable to take this medicine simultaneously each day with or without food. Swallow the capsule and do not crush, open, or dissolve them.